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Abstract Anakinra (Kineret), a recombinant form of
human interleukin-1 (IL-1) receptor antagonist, is approved
forthetreatmentofrheumatoidarthritis(RA)incombination
with methotrexate. Kineret is self-administered by daily
subcutaneous injections in patients with active RA. The
mechanism of action of anakinra is to competitively inhibit
the local inﬂammatory effects of IL-1. Kineret is generally
safe and well tolerated and the only major treatment-related
sideeffectsthatappearareskinreactionsattheinjectionsite.
Due to the relatively short half-life of anakinra, daily injec-
tion of the drug is required. This, in combination with the
comparably high rates of injection-site reactions (ISRs)
associated with the drug, can become a problem for the
patient. The present review summarises published data
concerning ISRs associated with Kineret and provides some
explanationsastotheircause.Theobjectiveisalsotopresent
some clinical experiences of how the ISRs can be managed.
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Background
Anakinra is a recombinant form of the human interleukin-1
receptor antagonist (IL-1Ra), r-metHuIL-1Ra, which is
produced by recombinant DNA technology in an E. coli
expression system. Anakinra is identical to native human
IL-1Ra, except for the addition of a single methionine resi-
due at its amino terminus [1]. Therapeutically, anakinra
neutralises the biological activity of IL-1a and b by com-
petitively inhibiting the two cytokines binding to the IL-1
receptor [2]. The maintenance of balance between IL-1 and
IL-1Ra is thought to be important in preventing the devel-
opmentofinﬂammatoryarthritis.Kineretisindicatedforthe
treatment of rheumatoid arthritis in adult patients, in the
European Union in combination with methotrexate in
patients with inadequate response to methotrexate alone, in
the United States also as monotherapy in patients failing at
leastonedisease-modifyinganti-rheumaticdrug(DMARD).
The recommended dose of Kineret is 100 mg administered
once daily via subcutaneous injection.
Injection-site reactions (ISR), often deﬁned as a constel-
lationofsymptomsincludingswelling,erythema,pruritusand
pain around the site of injection, is a common adverse event
associated with different kinds of biologic therapies [3], and
canpresentachallengetopatients.ISRsarethemostcommon
and consistently reported treatment-related adverse events
associated with Kineret. These are typically characterised by
oneormoreoferythema,ecchymosis,inﬂammationandpain.
In a review of ﬁve clinical trials, at doses of 50–150 mg/day,
the reported rates of ISRs were 71% for the anakinra-treated
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DOI 10.1007/s00296-011-2096-3groups versus 28% for patients receiving placebo [4]. The
median duration of the above-mentioned typical symptoms
was 14–28 days. The development of ISRs in patients who
hadnotpreviouslyexperiencedISRswasuncommonafterthe
ﬁrstmonthoftherapy.AsummaryofISRfrequenciesinsome
of the clinical studies with Kineret is presented in Table 1.
Contribution of vehicle constituents to ISRs
Early observations, in clinical trials with Kineret, indicated
that a substantial amount of patients had skin reactions
varying in intensity from mild to severe. This prompted
studies in both humans and rats in order to investigate if
vehicle and/or protein were capable of inducing non-
immunologically mediated cutaneous mast cell degranu-
lation [5]. Healthy volunteers received daily injections of
large doses (1 ml of up to 200 mg/ml) of IL-1Ra for
28 days. Intradermal testing after 28 injections demon-
strated that the response (erythema and oedema) for both
vehicle alone and rhuIL-1Ra in vehicle generally followed
the same pattern as that observed in histamine-injected
positive control sites. In rats, an intradermal testing assay
was used where extravasation of blue dye (injected in the
tail vein) was assessed 30 min after intradermal injections
of test solutions. All test solutions, which consisted of the
various components of the Kineret vehicle, induced per-
meability changes that were signiﬁcantly greater than those
occurring with PBS alone. Changing the vehicle to PBS
signiﬁcantly reduced the reactivity from that occurring
with rhuIL-1Ra in citrate buffer. However, the permeabil-
ity increase was still higher over that occurring with PBS
alone. Concurrent administration of diphenhydramine
(100 lg), an anti-histamine, and rhuIL-1Ra in citrate buffer
totally eliminated the permeability increase. Clearly, the
results of the study show that the components of the vehicle
have the potential to induce mast cell degranulation. But
the vehicle is not the sole cause of the reactions since
patients givenlower doses(1 ml of 20 mg/ml) ofrhuIL-1Ra
in vehicle have milder reactions. Thus, the combination
of vehicle constituents and a high protein concentration in
the syringe give rise to mast cell degranulation upon
subcutaneous injection [5]. In one of the dose-ﬁnding
studies with Kineret [6], it was also noted that the injec-
tion-site reactions were dose related. ISRs were experi-
enced by 28% of subjects in the placebo group and by 19,
38, 56, 64 and 63% in the groups receiving anakinra at
0.04, 0.1, 0.4, 1.0 and 2.0 mg/kg, respectively.
The placebo used in all clinical trials performed with
Kineret has consisted of the vehicle, i.e. the formulated
solution without protein. A considerable amount of patients
receiving placebo have also reported ISRs (see above). In
commercially available Kineret syringes, anakinra is for-
mulated in 10 mM sodium citrate, 140 mM NaCl, 0.5 mM
EDTA, and polysorbate 80 and has pH 6.5. The protein
concentration in the Kineret syringe is 100 mg/0.67 ml,
Table 1 Published clinical trials with Kineret
Reference N Therapy
a Frequency of IRSs
for each dose (%)
Concomitant drug use Withdrawal
rate
Dose
Bresnihan
et al. [24]
472 Mono 25, 50, 73, 81 NSAID, *85%; corticosteroid * 45% 5% in
150 mg/day
dose
Placebo, 30, 75,
150 mg/day
Nuki et al.
[25]
309 Mono,
extension
Similar to initial
24 weeks
As above As above As above
Cohen et al.
[6]
419 Combo
MTX
28, 19, 38, 56, 64, 63 NSAID, *70%; corticosteroid *45% 10% in
2.0 mg/kg
dose
0.04, 0.1, 0.4,
1.0, 2.0 mg/kg
Fleischmann
[26]
1399 Combo *70 NSAID, 86%; corticosteroid, 61%; MTX,
59%; other DMARDS, 48%
nd 100 mg/day
Cohen et al.
[27]
506 Combo
MTX
24, 65 NSAID, *75%; corticosteroid *52% 8.4% 100 mg/day
Fleischmann
et al. [28]
1346 Combo Exposure adjusted
event rates, EAE
NSAID, 87%; corticosteroids, 58%; MTX,
54%; other DMARDS, 78%
EAE rate 100 mg/day
den Broeder
et al. [14]
150 Combo 36 Corticosteroids, 46%; DMARDS 54%
(MTX, 35%)
None 100 mg/day
Karanikolas
et al. [15]
128 Combo 29 NSAIDS, 52%; corticosteroids, 62%;
DMARDS, 100%
nd 100 mg/day
Le Loet et al.
[29]
1207 Combo 62 DMARDS, 100% 6–10% 100 mg/day
a Mono mono therapy, Kineret only, Combo combination therapy
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123equivalent to 150 mg/ml. Potential reasons for pain upon
injection can be related to buffer (citrate), non-physiolog-
ical pH (6.5 vs. 7.2) and the presence of the surfactant
polysorbate 80.
The formulation strategy is primarily to achieve stability
of the protein, and the use of citrate in the Kineret for-
mulation has indeed structural biologic reasons. Highly
concentrated IL-1Ra solutions are prone to aggregate at
elevated temperature which is due to its predominant
b-barrel structural fold. This protein aggregation can be
suppressed by the presence of citrate in the solution.
Phosphate, for instance, is an approximately fourfold
weaker suppressant than citrate [7]. Sodium citrate is a
common buffering agent for parenteral drugs formulated
around pH 6 [8]. Furthermore, buffer concentration is a
factor that must be considered when designing injectable
presentations and low buffer concentrations (10 mM or
lower) are recommended to reduce injection pain caused by
buffer components [9].
It has previously been reported that a component part of
an epoetin a preparation caused pain after subcutaneous
injection. The pain experienced by the patients taking this
epoetin a preparation was described as stinging, burning
and itching, and it disappeared in most patients within
15 min. Differences in pain scores after subcutaneous
injection of the epoetin a solution and its vehicle were
assessed in a small trial with 36 volunteers, normal saline
serving as placebo control. It turned out that pain scores
with the vehicle or its citrate component were signiﬁcantly
higher than saline. The conclusion was that the local pain
experienced after subcutaneous administration of the
epoetin a solution was mainly due to the citrate component
of the buffered solution [10]. In a study on subcutaneous
delivery of typical buffers for human growth hormone
preparations in humans, 0.3 ml of buffer with sodium cit-
rate caused signiﬁcantly more injection pain when com-
pared to 0.3 ml saline [11].
Another component of the Kineret formulation is poly-
sorbate 80. This substance is commonly used in many
pharmaceuticals for its solubilising and stabilising effects.
There are some case reports of patients who developed
hypersensitivity reactions to erythropoietin. The sub-
sequent skin testing and clinical course suggested that the
reactions were due to the excipient polysorbate 80 [12].
Hence, in patients who develop hypersensitivity reactions
after subcutaneous injections of biological drugs, a control
of the presence of polysorbate 80 is valid.
Clinical experiences
The clinical experience indicates that there are two dif-
ferent types of ISRs in relation to injections of Kineret.
One immediate, with a stinging and burning feeling, and
one delayed, which presents with rash, swelling and pain.
Up to 70% of patients experience an ISR and of those 95%
are mild to moderate in severity. Onset of ISRs are gen-
erally within the ﬁrst weeks of initiating therapy, and
patients who do not experience an ISR within 4 weeks are
unlikely to experience any ISR. The incidence rate of ISRs
tends to diminish when patients are on concomitant oral
steroids [13–15].
The delayed type can present with a more severe reac-
tion involving erythema, pruritus, swelling and pain, i.e.
inﬂammatory lesions. Five patients were reported with
cutaneous drug reactions due to anakinra in 2005 [16]. A
histopathological study was performed on punch biopsy
specimens of skin lesions. Within the dermis, the most
striking feature was a prominent eosinophilic inﬁltrate with
a tendency to concentrate around vessels and surrounding
nerve ﬁbres. An increased number of spindle-shaped mast
cells and CD68? dermal macrophages was also seen,
characteristic of an allergic inﬂammation. The drug was
discontinued in two patients (systemic reaction in one)
while the other three completed the period of study but had
occasional reappearances of drug eruptions. The delayed
reaction may be treated with topical corticosteroids or anti-
histamines and, in the vast majority of cases, disappears
within 2 months.
The immediate ISRs with acute pain, experienced by
many patients, cannot to the same extent be relieved by the
remedies mentioned above. This reaction may, however, be
alleviated by placing a cool pack on the injection site for a
few minutes before and after the injection, thereby mildly
anaesthetising the subcutaneous nerves. Many physicians
assert that the immediate reaction is the one which is
hardest to endure and is the cause of many drop outs from
treatment with Kineret.
At our clinics (Nordstro ¨m, Pettersson and Knight), we
recently conducted a placebo-controlled trial with ana-
kinra in adult-onset Still’s disease. During this study,
patients were asked to apply a cool pack before and after
the injection and to warm the syringe in their hand before
injecting. Over 50% out of 12 patients experienced mild
ISRs, all of whom required or were offered antihistamines
and/or topical corticosteroids. Only one patient experi-
enced an intermediate ISR that subsided during follow-
up, and no patient withdrew from the study because of
ISRs.
Remedies to relieve ISRs
The clinical experiences put together can aid in the rec-
ommendation of remedies for the different kinds of ISRs.
As described above, to alleviate the acute pain (stinging,
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123burning) it is advised to warm the syringe, with its con-
tent, to room temperature before the injection and to
apply a cold pack to the injection site 2–3 min before and
immediately after the injection. The delayed reactions can
be mitigated by application of topical hydrocortisone or
anti-histamine cream, and it is recommended to alternate
the injection sites to avoid recall reactions. The clinical
understanding is also that they will disappear over time.
In our opinion, the single most important measure to
make patients manage both the acute and delayed ISRs is
to inform in advance about the potential for such reac-
tions. Convincing patients to remain motivated to push
beyond the weariness of injections and injection-site
reactions can be challenging, and these challenges have a
major impact on adherence. This has been particularly
true for patients suffering from multiple sclerosis, where
disease-modifying therapies are often burdened with ISRs
[17].
Discussion
ISRs related to some anti-TNFa therapies
Among other biological therapies, also the TNFa-inhibitors
are burdened with ISRs. Among patients receiving e.g.
Humira (adalimumab) and Enbrel (etanercept) typically
10–20% report ISRs [18]. Reactions to both therapies are
considered to be of the delayed type. The majority of
dermal inﬁltrate at the site of injection is composed of
CD4? T cells (CD8? T cells in recall reactions), indi-
cating a lymphocyte-mediated hypersensitivity reaction.
The ISRs present the ﬁrst month of treatment and usually
decrease in frequency with the continuation of therapy
[18]. In one case report for Enbrel, the histologic ﬁndings
differed considerably from the well-characterised Enbrel
ISRs reported in the literature. The dermal changes were
those of eosinophilic cellulitis, unlike the lymphocyte-rich
inﬁltrates seen in typical ISRs. The predominance of
eosinophils would point towards a role for IL-5 and a
mechanism more akin to a TH2 reaction. It was suggested
that the ISRs in this patient could be explained by the
rheumatoid factor autoantibody binding to the IgG Fc
component found in both Enbrel and Humira, since the
patient two weeks earlier had experienced the same type of
reaction against Humira [19]. In studies with Cimzia
(certolizumab pegol), the only PEGylated TNFa-inhibitor,
the overall tolerability proﬁle was similar to those of other
anti-TNFa agents but injection-site reactions were less
frequent and mild to moderate in nature. The inference
made was that the PEG-moiety inhibited non-immune
stimulated degranulation of mast cells which may explain
the low level of ISRs seen with this therapy [20].
Immunological clues
In vitro studies have shown that H1-blocking antihista-
mines reduce the release of proinﬂammatory mediators
from mast cells and basophils and also reduce the che-
motaxis and activation of inﬂammatory cells (especially
eosinophils) and the expression of adhesion molecules
induced by immunological and non-immunological stimuli
in epithelial cell lines [21]. Throughout the course of
allergic inﬂammation, the functional interface between
mast cells and eosinophils, which can be mediated by
soluble factors, is important in modulating the severity and/
or duration of the allergic response [22].
It is noteworthy that citric acid has been found to acti-
vate mast cells and cause airway constriction in guinea
pigs, and the subsequent analysis of BAL (bronchoalveolar
lavage) ﬂuid showed increased levels of histamine [23].
This is in accordance with the ﬁndings by Bendele et al. in
1995, reporting that the combination of vehicle constituents
and high protein concentration in the Kineret formulation
caused mast cell degranulation upon subcutaneous injec-
tion in rats and that this could be prevented by concomitant
injection of diphenhydramine. The clinical observations
that both the immediate and, principally, the delayed type
of injection-site reactions can be alleviated by topical
antihistamines, and corticosteroids can thus be explained
along this route.
Conclusion
The immediate and acute pain experienced by many
patients upon Kineret injection is caused by administration
of the vehicle constituents in combination with a relatively
large amount of anakinra in a highly concentrated protein
solution (as described in the ‘Background’), causing mast
cell degranulation. This reaction can be mitigated by some
simple remedies and it is thus very important that the
practitioners inform the patients about ISRs and how to
manage them. The delayed-type injection-site reactions
tend to be transient and can be tolerated by most patients
after adequate information. It is crucial to minimise the
impact of adverse effects in order to help patients adhere to
their treatment regimens.
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